GlobalData believes Shire-NPS deal to be 'robust'
Ireland-headquartered drugmaker Shire’s (LSE: SHP) deal to acquire NPS Pharmaceuticals (Nasdaq: NPSP) is ‘robust’, according to research and consulting firm GlobalData.
Despite the premium of more than 50% of NPS’s unaffected share price, the acquisition constitutes a robust deal. According to GlobalData’s net present value analysis, the combined discounted cash flow contribution from NPS’s lead assets alone is $4.9 billion, and Shire also stands to earn royalties of $300 million.
The move is intended to increase Shire’s rare disease drug portfolio, according to Chloe Thornton, an analyst with GlobalData, and relies on two key assets: Gattex (teduglutide) and Natpara (parathyroid hormone).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze